Immune Pharmaceuticals appoints Daniel Kazado chairman of the board
US-Israeli company Immune Pharmaceuticals (NASDAQ: IMNP) has appointed Daniel Kazado chairman of the board, succeeding Daniel Teper.
Dr Teper will continue as chief executive of Immune, while Mr Kazado has sat on the company’s board since 2013.
Immune's new chairman, Mr Kazado, said: "I am delighted to represent the interest of shareholders and to continue to support the strategic vision of Immune founder and CEO, Dr. Daniel Teper, to build a leading Antibody therapeutics company. We believe that the recently completed financing will allow Immune to conduct two Phase II proof of concept clinical trials with its lead drug, Bertilimumab. We believe that the partnering of our Phase III ready Neuropathic Pain drug, AmiKet, will allow to accelerate the development of NanomAbs, a novel Antibody Drug Conjugate platform, and to consider additional external growth opportunities with a focus on clinical stage assets."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze